GHRP-6

What it is

GHRP-6 is a synthetic hexapeptide and one of the earliest growth-hormone-releasing peptides characterised. It predates the discovery of ghrelin, which is the historically interesting part: GHRP-6 and its relatives were found to stimulate growth-hormone release through a receptor nobody had identified yet.

That orphan receptor was designated the growth-hormone secretagogue receptor, GHS-R1a. Ghrelin — the endogenous ligand — was not identified until 1999, several years after the synthetic peptides that act on it were already in use as research tools. GHRP-6 is, in effect, how the receptor was found.

Why it is still used as a reference tool

GHRP-6 is a full GHS-R1a agonist and, importantly for comparative work, a non-selective one. Alongside growth-hormone release it produces marked effects on appetite signalling and measurable increases in cortisol and prolactin in preclinical models.

Those off-target effects are precisely why it remains a useful reference compound. When a newer secretagogue such as ipamorelin is characterised as selective, that claim is made against something — and GHRP-6 is usually the something. It defines the non-selective end of the range, so the selectivity of anything else can be quantified relative to it.

Its appetite-signalling activity also made it a standard tool in ghrelin-pathway research more broadly, independent of the growth-hormone axis. Studies of GHS-R1a expression, receptor distribution and downstream signalling frequently use GHRP-6 as the probe agonist.

Where it sits among the secretagogues

GHS-R1a agonists differ mainly in selectivity. GHRP-6 is potent and non-selective. GHRP-2 is more potent with a somewhat different profile. Hexarelin is more potent again but shows pronounced desensitisation with repeated exposure. Ipamorelin is the selective member of the family: it stimulates growth-hormone release with minimal effect on cortisol and prolactin, which is the property that made it the more commonly used research standard.

Comparing across that range is how the structure-activity relationships of the receptor were mapped, and it is why several of these compounds continue to appear in the literature despite newer alternatives existing.

Desensitisation, and why it separates these compounds

Repeated or sustained agonist exposure at GHS-R1a produces receptor desensitisation, and members of this family differ substantially in how fast it sets in. Hexarelin is the usual example of pronounced desensitisation; others are less affected under comparable conditions.

For experimental design that is not a footnote. A protocol with repeated exposure will record a declining response for a compound that desensitises quickly, and the decline is a property of the tool rather than a finding about the biology. Single-exposure and repeated-exposure designs can disagree for entirely mechanical reasons.

GHS-R1a also shows unusually high constitutive activity — measurable signalling with no ligand present. That complicates potency comparisons, because the quantity of interest is an increment above a floor that is not zero, and it is one reason inverse agonists at this receptor are studied alongside agonists.

The historical order matters when reading the literature

The synthetic secretagogues came before the endogenous ligand. GHRP-6 and its relatives were characterised, their receptor was identified as an orphan, and ghrelin was found afterwards by working backwards from the receptor — reverse pharmacology, and one of its cleaner successes.

That sequence is worth knowing. Work published before 1999 describes activity at a receptor whose natural ligand was unknown, so its framing and terminology differ from anything written after, and the two literatures do not always use the same names for the same things.

Not stocked here

We do not sell GHRP-6. We stock Ipamorelin, the selective GHS-R1a agonist in the same family, and this entry exists because GHRP-6 is the compound that selectivity is defined against.

For laboratory research use only. Findings summarised here are preclinical.